Edition:
United States

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

4.15USD
12:42pm EDT
Change (% chg)

$-0.10 (-2.35%)
Prev Close
$4.25
Open
$4.25
Day's High
$4.25
Day's Low
$4.13
Volume
4,694
Avg. Vol
15,880
52-wk High
$6.34
52-wk Low
$2.65

Chart for

About

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $40.29
Shares Outstanding(Mil.): 9.57
Dividend: --
Yield (%): --

Financials

  CLBS.OQ Industry Sector
P/E (TTM): 3.01 223.30 32.53
EPS (TTM): 1.41 -- --
ROI: 40.60 -8.07 12.63
ROE: 50.59 -10.87 14.50

BRIEF-Caladrius Biosciences Reports Q1 Loss Per Share $0.52 From Continuing Operations

* CALADRIUS BIOSCIENCES REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

May 10 2018

BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia

* CALADRIUS BIOSCIENCES RECEIVES SAKIGAKE EXPEDITED REVIEW DESIGNATION IN JAPAN FOR CLBS12 FOR TREATING CRITICAL LIMB ISCHEMIA Source text for Eikon: Further company coverage:

Apr 10 2018

BRIEF-Caladrius Biosciences Q4 Loss Per Share $0.40 From Cont Ops

* CALADRIUS BIOSCIENCES REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS

Mar 22 2018

BRIEF-Caladrius Biosciences Doses First Patient In Mid-Stage Critical Limb Ischemia Trial In Japan

* CALADRIUS BIOSCIENCES DOSES FIRST PATIENT WITH CLBS12 IN PHASE 2 CRITICAL LIMB ISCHEMIA TRIAL IN JAPAN Source text for Eikon: Further company coverage:

Mar 13 2018

BRIEF-Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program

* CALADRIUS BIOSCIENCES ACQUIRES AN EXCLUSIVE LICENSE TO A LATE STAGE CD34+ CELL THERAPY PROGRAM FOR THE TREATMENT OF REFRACTORY ANGINA

Mar 06 2018

BRIEF-Caladrius Biosciences Entered Common Stock Sales Agreement With H.C. Wainwright & Co

* CALADRIUS BIOSCIENCES INC - ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO HAVING AGGREGATE OFFERING PRICE OF UP TO $12 MILLION Source text: (http://bit.ly/2ER7sY9) Further company coverage:

Feb 08 2018

Earnings vs. Estimates